Ultragenyx Pharmaceutical Inc. RARE
16.63 USD +0.33 (+2.02%)
At closeNov 3, 2026, 7:54 PM EST
15.80 -0.83 -4.99%
After hours · Nov 3, 7:54 PM ET
16.39 Day range 16.99
12.73 52-week range 39.89
- YTD
- -27.70%
- 1 year
- -50.31%
Analyst view
Consensus: buy
Buy
Price target (mean) 26.25 +57.8% upside
Now 16.63
- Target (low)
- 16.00
- Target (mean)
- 26.25
- Target (high)
- 39.00
Ratings (0m) 21 10 buy · 11 hold · 0 sell
- Strong buy2
- Buy8
- Hold11
- Sell0
- Strong sell0
Recommendation trend
- This month 21
- 1 month ago 20
- 2 months ago 20
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.75132 | -1.25 – 0.75 | -1.81 | +58.5% | 183.71M | +14.9% | 6 |
| Next quarter | -0.66246 | -1.08 – 0.78 | -1.29 | +48.7% | 229.66M | +10.9% | 6 |
| Current year | -4.08 | -4.96 – -1.18 | -5.83 | +30.1% | 760.21M | +13.0% | 6 |
| Next year | 0.22559 | -1.69 – 4.50 | -4.08 | +105.5% | 997.05M | +31.1% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 15, 2026 | UBS | Initiated | — | Neutral |
| Sep 21, 2026 | Evercore ISI Group | Maintained | In-Line | In-Line |
| Sep 21, 2026 | Barclays | Maintained | Overweight | Overweight |
| Sep 18, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Sep 18, 2026 | Citigroup | Maintained | Buy | Buy |
| Sep 18, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Sep 18, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Sep 17, 2026 | Citigroup | Maintained | Buy | Buy |
| Sep 4, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Sep 4, 2026 | Barclays | Maintained | Overweight | Overweight |
| Sep 3, 2026 | JP Morgan | Downgrade | Overweight | Neutral |
| Sep 3, 2026 | Jefferies | Maintained | Buy | Buy |
| Sep 3, 2026 | William Blair | Downgrade | Outperform | Market Perform |
| Sep 3, 2026 | Citigroup | Maintained | Buy | Buy |
| Sep 3, 2026 | TD Cowen | Maintained | Buy | Buy |
| Sep 3, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Sep 3, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Sep 3, 2026 | Wedbush | Maintained | Neutral | Neutral |
| Sep 3, 2026 | Evercore ISI Group | Downgrade | Outperform | In-Line |
| Sep 3, 2026 | Baird | Downgrade | Outperform | Neutral |
| Sep 3, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 3, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Aug 28, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Aug 25, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 21, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 20, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 20, 2026 | Citigroup | Maintained | Buy | Buy |
| Aug 20, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Aug 20, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Aug 10, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |